2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2819

The YAP Pathway Regulates Fibroblast-like Synoviocyte Invasion
Abstract Number: 2347

Therapeutic Effect of a Novel Histone Deacetylase 6 Inhibitor, CKD-L, on Collagen Induced Arthritis and Peripheral Blood Mononuclear Cells from Patients with Rheumatoid Arthritis
Abstract Number: 2343

Therapeutic Effects of Mesenchymal Stem Cells, Anti-Tumor Necrosis Factor and Anti-CD20 Treatment on Collagen Induced Arthritis
Abstract Number: 1512

Therapeutic Efficacy of a Novel Oral Small Molecule Macrophage Migration Inhibitory Factor [MIF] Inhibitor: A Promising Safe & Efficacious Treatment for Rheumatoid Arthritis
Abstract Number: 1726

Therapeutic Efficacy of Mesenchymal Stem Cells in Diffuse Murine Hypochlorite-Induced Systemic Sclerosis
Abstract Number: 1034

Therapeutic Potential of Targeting Sialic Acid Modified Receptors in Osteoarthritis
Abstract Number: 558

Therapeutic Response in Adalimumab-Treated Patients with Non-Radiographic Axial Spondyloarthritis Is Similar Regardless of Body Mass Index
Abstract Number: 573

Three-Year Course and Prediction of Physical Functioning in Ankylosing Spondylitis Patients Treated with TNF-Inhibitors
Abstract Number: 2

Thrombocytopenia in Primary Antiphospholipid Syndrome Is Related to Arterial Thrombosis
Abstract Number: 1634

Thrombophilia Associated with DFS70 Antibodies
Abstract Number: 1980

Thrombospondin-1 Is Elevetad in the Plasma of Patients with Antiphospholipid Syndrome and Is Correlated with Soluble Fas Ligand and Free Active TGF-B levels
Abstract Number: 1654

Thrombotic Microangiopathy and Poor Renal Outcome in Lupus Patients Is Not Associated with Antiphospholipid Syndrome and/or Other Lupus Conventional Features
Abstract Number: 1052

Time Trends in Comorbidities Among Patients with Rheumatoid Arthritis Compared to the General Population
Abstract Number: 188

Time Trends in Total Ankle Arthroplasty in the U.S.: A Study of the Nationwide Inpatient Sample
Abstract Number: 2814

Time-to-Remission, Time-to-Relapse and Disease Severity at the Time of Relapse in RA- Results from the Ontario Best Practices Research Initiative (OBRI)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].